Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00435695
Status:
COMPLETED
Last Update Posted:
2012-06-04
First Post:
2007-02-13
Brief Title:
Study Of Safety Blood Levels And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Open Label Non-randomized Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain 5-HT1A Receptor Occupancy Pharmacokinetics and Safety of Single Oral Doses of GSK163090 Using the Ligand 11C-WAY100635
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to look at how much of a new drug GSK163090 binds to proteins in the brain and how much stays in the blood over a range of different doses This study will use a medical imaging technique called Positron Emission Tomography PET which uses an imaging agent called 11C-WAY100635
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None